Loading...
•
Jun 30, 2022
Surmodics Q3 2022 Earnings Report
Reported a revenue increase of 4% year-over-year, with GAAP EPS of $(0.41) and non-GAAP EPS of $(0.34).
Key Takeaways
Surmodics reported solid financial results for Q3 2022, with revenue of $24.9 million, a 4% increase year-over-year. The company delivered double-digit product sales growth for the fourth consecutive quarter and is making meaningful investments in growth initiatives. However, the company reported a GAAP EPS loss of $(0.41) and a non-GAAP EPS loss of $(0.34).
Revenue of $24.9 million, an increase of 4% year-over-year
GAAP EPS of $(0.41), non-GAAP EPS of $(0.34)
Fourth consecutive quarter of double‐digit product sales growth year‐over‐year
Demonstrating early and promising commercial viability for PounceTM and SublimeTM products
Surmodics
Surmodics
Surmodics Revenue by Segment
Revenue by Segment
Medical Device Revenue
CapyFin.comIn Vitro Diagnostics Revenue
CapyFin.com Forward Guidance
Surmodics is revising its fiscal year 2022 revenue guidance to reflect expected softness in customer demand and raising its fiscal year 2022 EPS guidance to reflect solid year-to-date results. Surmodics expects full year fiscal 2022 revenue to range from $97 million to $99 million. Surmodics expects fiscal 2022 diluted GAAP EPS to a range from a loss per share of $(1.50) to $(1.35). Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.23) to $(1.08).
Revenue & Expenses
Visualization of income flow from segment revenue to net income